Common use of Securities Purchased Clause in Contracts

Securities Purchased. At the closings of the transactions contemplated hereby (the “Closings”), the Company will sell and the Purchaser will purchase the following securities of the Company for an aggregate purchase price of up to one million two hundred thousand dollars ($1,200,000) (the “Purchase Price”), as follows: (i) One million five hundred thousand (1,500,000) shares of Common Stock $0.00001 par value at a price of $0.40 per share, or an aggregate purchase price of six hundred thousand dollars ($600,000) (the “Initial Shares”); (ii) The Purchaser has the option, to notify the Company (the “Second Closing Notice”) no later than ten (10) business days following the release of an official announcement by the Company that it is initiating its first human clinical trials, of Purchaser’s agreement to purchase an additional eight hundred thousand (800,000) shares of Common Stock $0.00001 par value at a purchase price of $0.75 per share, or an aggregate purchase price of six hundred thousand dollars ($600,000) (the “Additional Shares”); and (iii) Warrants to purchase up to an additional one million five hundred thousand (1,500,000) shares of Common Stock with an exercise price of $1.00 per share, which will be issued to Purchaser at the Closing of the Initial Shares purchase (the “First Warrant”). In the event that Purchaser exercises the option mentioned in (ii) above, the Company will issue warrants to purchase up to an additional eight hundred thousand (800,000) shares of Common Stock with an exercise price of $1.50 per share (the “Second Warrant”). No separate consideration shall be paid for either the First Warrant or the Second Warrant (collectively, the “Warrants”). The Warrants are five-year warrants and shall be in the form previously provided to the Purchaser. (The Initial Shares and the Additional Shares are sometimes referred to as the “Shares”, the shares issuable upon exercise of the Warrants are sometimes referred to as the “Warrant Shares” and all of the foregoing are sometimes referred to as the “Securities”.)

Securities Purchased. At the closings of the transactions transaction contemplated hereby (the “ClosingsClosing”), the Company will sell and the Purchaser will purchase the following securities of the Company for an aggregate purchase price of up to one million two hundred thousand dollars US$1,250,000 ($1,200,000One Million Two Hundred and Fifty Thousand US dollars) (the “Purchase Price”), as follows: (i) One million five hundred thousand 12,500,000 (1,500,000Twelve Million Five Hundred Thousand ) shares of the Company’s Common Stock $0.00001 0.001 par value at a price of $0.40 0.10 per share, or an aggregate purchase price of six hundred thousand dollars US$1,250,000 ($600,000One Million Two Hundred and Fifty Thousand US dollars) (the “Initial Shares”); (ii) The Purchaser has the option, to notify the Company (the “Second Closing Notice”) no later than ten (10) business days following the release of an official announcement by the Company that it is initiating its first human clinical trials, of Purchaser’s agreement to purchase an additional eight hundred thousand (800,000) shares of Common Stock $0.00001 par value at a purchase price of $0.75 per share, or an aggregate purchase price of six hundred thousand dollars ($600,000) (the “Additional Shares”); and (iiiii) Warrants Five year warrant to purchase up to an additional one million five hundred thousand 6,250,000 (1,500,000Six Million Two Hundred and Fifty Thousand) shares of the Company’s Common Stock $0.001 par value with an exercise price of $1.00 0.10 per share, which will be issued to the Purchaser at the Closing of the Initial Shares purchase and will be exercisable only after six months from Closing (the “First "Warrant”). In the event that Purchaser exercises the option mentioned in (ii) above, the Company will issue warrants to purchase up to an additional eight hundred thousand (800,000) shares of Common Stock with an exercise price of $1.50 per share (the “Second Warrant”"). No separate consideration shall be paid for either the First Warrant or the Second Warrant (collectively, the “Warrants”)Warrant. The Warrants are five-year warrants and Warrant shall be in the form previously provided to appended hereto as Annex "A" (the Purchaser. (The Initial Shares and shares issuable upon the Additional Shares exercise of the Warrant are sometimes referred to hereinafter as the “"Warrant Shares”, " and the shares issuable upon exercise of Shares and the Warrants Warrant Shares are sometimes sometime referred to hereinafter as the “Warrant Shares” and all of the foregoing are sometimes referred to as the “"Securities”").)

Securities Purchased. At the closings of the transactions contemplated hereby (the “Closings”), Closing the Company will sell and the Purchaser will purchase the following securities of the Company for an aggregate purchase price of up to one million two hundred thousand dollars $6,000,000 ($1,200,000Six Million U.S. Dollars) (the “Purchase Price”)) to be transferred as set forth on Schedule 1.1(c) attached hereto, as follows: (i) One million five hundred thousand 30,000,000 (1,500,000Thirty Million) shares of the Company’s Common Stock $0.00001 0.001 par value at a price of $0.40 0.20 per share, or share corresponding to an aggregate purchase price of six hundred thousand dollars $6,000,000 ($600,000) (the “Initial Shares”); (ii) The Purchaser has the option, to notify the Company (the “Second Closing Notice”) no later than ten (10) business days following the release of an official announcement by the Company that it is initiating its first human clinical trials, of Purchaser’s agreement to purchase an additional eight hundred thousand (800,000) shares of Common Stock $0.00001 par value at a purchase price of $0.75 per share, or an aggregate purchase price of six hundred thousand dollars ($600,000) (the “Additional Shares”Six Million U.S. Dollars); and (iiiii) Warrants Sixty (60) months warrant to purchase up to an additional one million five hundred thousand 26,666,667 (1,500,000Twenty Six Million Six Hundred and Sixty Six Thousand and Six Hundred and Sixty Seven) shares of the Company’s Common Stock $0.001 par value with an exercise price of $1.00 0.225 per share, which will be issued to the Purchaser at the Closing of the Initial Shares purchase and will be exercisable only after six months from Closing (the “First "Warrant”). In the event that Purchaser exercises the option mentioned in (ii) above, the Company will issue warrants to purchase up to an additional eight hundred thousand (800,000) shares of Common Stock with an exercise price of $1.50 per share (the “Second Warrant”"). No separate consideration shall be paid for either the First Warrant or issuance of the Second Warrant (collectively, the “Warrants”)Warrant. The Warrants are five-year warrants and Warrant shall be in the form previously provided to appended hereto as Exhibit "A" (the Purchaser. (The Initial Shares and shares issuable upon the Additional Shares exercise of the Warrant are sometimes referred to hereinafter as the “"Warrant Shares”, " and the shares issuable upon exercise of Shares and the Warrants Warrant Shares are sometimes sometime referred to hereinafter as the “Warrant Shares” and all of the foregoing are sometimes referred to as the “"Securities”").)

Securities Purchased. At the closings of the transactions contemplated hereby (the “Closings”), Closing the Company will sell and the Purchaser will purchase the following securities of the Company for an aggregate purchase price of up to one million two hundred thousand dollars ($1,200,000) US$ __________ (the “Purchase Price”), as follows: (i) One million five hundred thousand (1,500,000) shares of the Company’s Common Stock $0.00001 0.001 par value at a price of $0.40 per share, or 0.19078 corresponding to an aggregate purchase price of six hundred thousand dollars ($600,000) (the “Initial Shares”);__________ US$ ; and (ii) The Purchaser has the option, to notify the Company Twenty four (the “Second Closing Notice”24) no later than ten (10) business days following the release of an official announcement by the Company that it is initiating its first human clinical trials, of Purchaser’s agreement to purchase an additional eight hundred thousand (800,000) shares of Common Stock $0.00001 par value at a purchase price of $0.75 per share, or an aggregate purchase price of six hundred thousand dollars ($600,000) (the “Additional Shares”); and (iii) Warrants months warrant to purchase up to an additional one million five hundred thousand (1,500,000) ___________ shares of the Company’s Common Stock $0.001 par value with an exercise price of $1.00 $ 0.19078 per share, which will be issued to the Purchaser at the Closing of the Initial Shares purchase and will be exercisable only after six months from Closing (the “First "Warrant”). In the event that Purchaser exercises the option mentioned in (ii) above, the Company will issue warrants to purchase up to an additional eight hundred thousand (800,000) shares of Common Stock with an exercise price of $1.50 per share (the “Second Warrant”"). No separate consideration shall be paid for either the First Warrant or issuance of the Second Warrant (collectively, the “Warrants”)Warrant. The Warrants are five-year warrants and Warrant shall be in the form previously provided to appended hereto as Annex "A" (the Purchaser. (The Initial Shares and shares issuable upon the Additional Shares exercise of the Warrant are sometimes referred to hereinafter as the “"Warrant Shares”, " and the shares issuable upon exercise of Shares and the Warrants Warrant Shares are sometimes sometime referred to hereinafter as the “Warrant Shares” and all of the foregoing are sometimes referred to as the “"Securities”").)

Securities Purchased. At the closings of the transactions contemplated hereby (the “Closings”), Closing the Company will sell and the Purchaser will purchase the following securities of the Company for an aggregate purchase price of up to one million two US$ 724,000 (Seven hundred thousand dollars ($1,200,000twenty- four thousand) (the “Purchase Price”), as follows: (i) One million five 3,794,947 (Three million, seven hundred ninety four thousand (1,500,000and nine hundred forty seven) shares of the Company’s Common Stock $0.00001 0.001 par value at a price of $0.40 per share, or 0.19078 corresponding to an aggregate purchase price of six US$ 724,000 (Seven hundred thousand dollars ($600,000twenty -four thousand) (the “Initial Shares”);; and (ii) The Purchaser has the option, to notify the Company Sixty (the “Second Closing Notice”60) no later than ten (10) business days following the release of an official announcement by the Company that it is initiating its first human clinical trials, of Purchaser’s agreement to purchase an additional eight hundred thousand (800,000) shares of Common Stock $0.00001 par value at a purchase price of $0.75 per share, or an aggregate purchase price of six hundred thousand dollars ($600,000) (the “Additional Shares”); and (iii) Warrants months warrant to purchase up to an additional 1,138,484 (One million, one million five hundred thirty-eight thousand (1,500,000and four hundred eighty-four) shares of the Company’s Common Stock $0.001 par value with an exercise price of $1.00 $ 0.19078 per share, which will be issued to the Purchaser at the Closing of the Initial Shares purchase and will be exercisable only after six months from Closing (the “First "Warrant”). In the event that Purchaser exercises the option mentioned in (ii) above, the Company will issue warrants to purchase up to an additional eight hundred thousand (800,000) shares of Common Stock with an exercise price of $1.50 per share (the “Second Warrant”"). No separate consideration shall be paid for either the First Warrant or issuance of the Second Warrant (collectively, the “Warrants”)Warrant. The Warrants are five-year warrants and Warrant shall be in the form previously provided to appended hereto as Annex "A" (the Purchaser. (The Initial Shares and shares issuable upon the Additional Shares exercise of the Warrant are sometimes referred to hereinafter as the “"Warrant Shares”, " and the shares issuable upon exercise of Shares and the Warrants Warrant Shares are sometimes sometime referred to hereinafter as the “Warrant Shares” and all of the foregoing are sometimes referred to as the “"Securities”").)